AMICUS THERAPEUTICS, INC. (FOLD)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net product sales | 154,688 | 125,249 | 141,517 | 126,669 |
| Cost of goods sold | 15,217 | 11,698 | 13,279 | 11,261 |
| Gross profit | 139,471 | 113,551 | 128,238 | 115,408 |
| Selling, general, and administrative | 84,543 | 91,827 | 75,106 | 73,576 |
| Restructuring charges | - | - | 3,143 | - |
| Research and development | 60,848 | 27,839 | 26,160 | 24,683 |
| Depreciation and amortization | 1,852 | 1,837 | 2,170 | 2,182 |
| Loss on impairment of assets | 1,702 | - | - | - |
| Total operating expenses | 148,945 | 121,503 | 106,579 | 100,441 |
| Loss from operations | -9,474 | -7,952 | 21,659 | 14,967 |
| Interest income | 843 | 812 | 1,081 | 1,370 |
| Interest expense | 11,565 | 11,455 | 12,692 | 12,512 |
| Other income (expense) | 1,015 | 550 | -3,263 | -3,717 |
| Loss before income tax | -19,181 | -18,045 | 6,785 | 108 |
| Income tax expense | 5,239 | 3,641 | 13,514 | 15,805 |
| Net loss attributable to common stockholders | -24,420 | -21,686 | -6,729 | -15,697 |
| Net loss attributable to common stockholders per common share - basic (in dollars per share) | -0.08 | -0.07 | -0.02 | -0.05 |
| Net loss attributable to common stockholders per common share diluted (in dollars per share) | -0.08 | -0.07 | -0.02 | -0.05 |
| Weighted average common shares outstanding - basic (in shares) | 308,254,256 | 307,689,207 | 304,690,596 | 303,773,922 |
| Weighted average common shares outstanding - diluted (in shares) | 308,254,256 | 307,689,207 | 304,690,596 | 303,773,922 |